+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.

Age: 18Years +All GendersPhase 3
671 locations
R

Actively Recruiting

Researchers are evaluating the real-world effectiveness of a fixed triple inhaled combination therapy called Trimbow 17259 g pMDI in adults with asthma. This study focuses on patients with severe asthma who have been treated for at least three years but still have uncontrolled symptoms despite using other inhaled therapies. The research aims to assess improvements in asthma symptom scores over six months after switching to Trimbow, as well as treatment adherence and lung function. The study is a multicenter, national, prospective, non-interventional design where patients are observed after their doctors independently decide to switch their inhaled therapy to Trimbow 17259 g pMDI. The recommended dose is two inhalations twice daily. Participants will be followed for six months, with assessments at enrollment, one month, and six months. If their asthma treatment changes away from Trimbow during the study, they are excluded. Other asthma medications and reliever inhalers are allowed as usual. Participants will attend three visits during routine clinical care where researchers will collect information on demographics, medical history, asthma control test ACT scores, lung function if available, medication adherence using a questionnaire, and any changes in asthma treatment. The main measure is the change in ACT score over six months. Secondary measures include lung function improvement and adherence to treatment. Safety and treatment changes are monitored throughout the study, which is expected to run from November 2024 to June 2026.

Age: 18Years +All Genders
18 locations